Vallon Pharmaceuticals, Inc. (VLON)
Market Closed
13 Jun, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
1. 30
-0.1
-7.14%
$
5.39M Market Cap
- P/E Ratio
0% Div Yield
113,343 Volume
- Eps
$ 1.4
Previous Close Day Range
1.3 1.42
Year Range
0.2 10.99
Summary
VLON closed Friday lower at $1.3, a decrease of 7.14% from Thursday's close, completing a monthly increase of 0% or $0. Over the past 12 months, VLON stock gained 54.76%.
VLON is not paying dividends to its shareholders.
The last earnings report, released on Feb 22, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Vallon Pharmaceuticals, Inc. has completed 2 stock splits, with the recent split occurring on Jan 30, 2024.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Want to track VLON and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
VLON Chart
Loading, please wait...
Vallon Pharmaceuticals, Inc. Dividends
VLON is not paying dividends to its shareholders.
Vallon Pharmaceuticals, Inc. Earnings
| 22 Feb 2024 Date | | - Cons. EPS | - EPS |
| 1 Nov 2023 Date | | - Cons. EPS | - EPS |
VLON is not paying dividends to its shareholders.
| 22 Feb 2024 Date | | - Cons. EPS | - EPS |
| 1 Nov 2023 Date | | - Cons. EPS | - EPS |
Vallon Pharmaceuticals, Inc. (VLON) FAQ
What is the stock price today?
The current price is $1.30.
On which exchange is it traded?
Vallon Pharmaceuticals, Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is VLON.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 5.39M.
Has Vallon Pharmaceuticals, Inc. ever had a stock split?
Vallon Pharmaceuticals, Inc. had 2 splits and the recent split was on Jan 30, 2024.
Vallon Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. David C. Baker CEO | NASDAQ (CM) Exchange | 92023M101 Cusip |
| US Country | 2 Employees | - Last Dividend | 18 Jun 2024 Last Split | - IPO Date |
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Contact Information
Address: Two Logan Square
Phone: 267 607 8255
Website: https://www.vallon-pharma.com
2025 © Marketlog. All Rights Reserved.
